|
|
|
|
Emergent BioSolutions to Webcast Presentation at the 6th Annual Southwestern Showcase Investor Conference on N
- Emergent BioSolutions Inc.(NYSE:EBS) announced today that the company will be webcasting its presentation at the 6 th Annual Southwestern Showcase Investor Conference scheduled for Thursday, November 20, 2008 at 1:40 pm Central. A...
|
|
|
PharmAthene signs deal with Israeli firm to market biodefense drugs
PharmAthene Inc.has signed a deal with Medison Pharma Ltd. to commercialize its biodefense drugs in Israel. Medison, based in Petach Tikva, Israel, gets an exclusive license to shepherd drugs from Annapolis-based PharmAthenes pipeline...
|
|
|
University of Central Florida
4000 Central Florida Boulevard Orlando Florida 32816 U.S.A.Phone: 407-823-2000 Fax: Industry Company News Two New Compounds Show Promise For Eliminating Breast Cancer Tumors, Study 11/19/2008 7:19:13 AM More... University of Central...
|
|
|
PharmAthene signs deal with Israeli firm to market biodefense drugs
Medison, based in Petach Tikva, Israel, gets an exclusive license to shepherd drugs from Annapolis-based PharmAthenes pipeline to that countrys commercial marketplace everything from gaining regulatory approval to overseeing marketing and...
|
|
|
Enigma Diagnostics Launches Field Laboratory (FL) System, Fully Automated Real-Time PCR for In-Field Testing
PORTON DOWN, England, Nov.18 /PRNewswire/ -- Enigma Diagnostics, the decentralised and point-of-care molecular diagnostics company, announces the launch of its upgraded version of Enigma FL at the XIth International CBRN Defence Symposium...
|
|
|
Noble, Inc. Entertainment Security & BioDefense Corp. Strike Alliance
Noble, Inc.Entertainment Security (http://www.nobleincsecurity.com), one of the largest and most-respected full-service professional security agencies nationwide, has signed an exclusive alliance with BioDefense Corporation (http://www...
|
|
|
Disaster planning should be priority for hospital pharmacists, experts say
Disasters should be defined broadly The past decade has featured devastating hurricanes, floods, fires, and terrorist acts that have captured headlines often for weeks at a time.What the nation's heightened awareness of disasters has...
|
|
|
Emergent BioSolutions Files Universal Shelf Registration Statement
ROCKVILLE, Md.-- (BUSINESS WIRE) -- Emergent BioSolutions Inc.(NYSE:EBS) announced today that it has filed with the U.S. Securities and Exchange Commission (SEC) a universal shelf registration statement which, when declared effective,...
|
|
|
Pharmathene Reports Third Quarter 2008 Financial and Operational Results
ANNAPOLIS, Md., Nov.13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter...
|
|
|
Pharmathene Reports Third Quarter 2008 Financial and Operational Results
ANNAPOLIS, Md., Nov.13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter...
|
|
|
Pharmathene Reports Third Quarter 2008 Financial and Operational Results
ANNAPOLIS, Md., Nov.13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter...
|
|
|
Pharmathene Reports Third Quarter 2008 Financial and Operational Results
ANNAPOLIS, Md., Nov.13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter...
|
|
|
Pharmathene Reports Third Quarter 2008 Financial and Operational Results
ANNAPOLIS, Md., Nov.13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter...
|
|
|
Emergent BioSolutions Files Universal Shelf Registration Statement
- Emergent BioSolutions Inc.(NYSE:EBS) announced today that it has filed with the U.S. Securities and Exchange Commission (SEC) a universal shelf registration statement which, when declared effective, will permit the company to issue up...
|
|
|
Response Biomedical Corporation Announces Third Quarter Results
VANCOUVER, Nov.13 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $1,471,130 and a net loss of $3,648,602 or ($0.03) per share for the three month period ended...
|
|
|
Response Biomedical Corporation Announces Third Quarter Results
Company Reports Record Revenues - Increasing Product Sales Trend Expected to Continue VANCOUVER, Nov.13 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $1,471...
|
|
|
Response Biomedical Corporation Announces Third Quarter Results
Company Reports Record Revenues - Increasing Product Sales Trend Expected to Continue VANCOUVER, Nov.13 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $1,471...
|
|
|
Response Biomedical Corporation Announces Third Quarter Results
Company Reports Record Revenues - Increasing Product Sales Trend Expected to Continue VANCOUVER, Nov.13 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $1,471...
|
|
|
Response Biomedical Corporation Announces Third Quarter Results
Company Reports Record Revenues - Increasing Product Sales Trend Expected to Continue VANCOUVER, Nov.13 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $1,471...
|
|
|
Response Biomedical Corporation Announces Third Quarter Results
Company Reports Record Revenues - Increasing Product Sales Trend Expected to Continue VANCOUVER, Nov.13 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $1,471...
|
|
|
Aradigm Announces Third Quarter 2008 Financial Results
Aradigm Corporation (OTCBB:ARDM) (the 'Company') today announced financial results for the third quarter and nine months ended September 30, 2008.Revenue for the third quarter was $197,000, compared with revenue of $230,000 for the third...
|
|
|
Some Stocks At 52 Week High-AFAM,EBS,CBST
Symbols: AFAM, CBST, EBS Author Alerts by Email We never spam!Related RSS Feeds AFAM Headline Feed CBST Headline Feed EBS Headline Feed All Symbols Sector Feeds: Buoyed by China stimulus plan, US stocks opened with strong gains! However...
|
|
|
Aradigm Completes Study of Inhaled Treprostinil with AERx(R) Inhaler
HAYWARD, Calif.-- (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) Data from the study showed that the AERx Essence inhaler efficiently delivered aerosolized treprostinil deeper into the lung than delivery by the OPTINEB nebulizer.
|
|
|
Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
ROCKVILLE, Md., Nov.6 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results and key developments for the quarter ended September 30, 2008. (Logo: http://www.newscom.com/cgi-bin/prnh...
|
|
|
Aradigm Completes Study of Inhaled Treprostinil with AERx(R) Inhaler
- Aradigm Corporation (OTCBB:ARDM) Data from the study showed that the AERx Essence inhaler efficiently delivered aerosolized treprostinil deeper into the lung than delivery by the OPTINEB nebulizer.Inhaled treprostinil was well tolerated...
|
